Cargando…
Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia
Finding synergistic drug combinations is an important area of cancer research. Here, we sought to rationally design synergistic drug combinations with an inhibitor of BTK kinase, ibrutinib, which is used for the treatment of several types of leukemia. We (a) used a pooled shRNA screen to identify ge...
Autores principales: | Hezkiy, Eleonora Ela, Kumar, Santosh, Gahramanov, Valid, Yaglom, Julia, Hesin, Arkadi, Jadhav, Suchita Suryakant, Guzev, Ekaterina, Patel, Shivani, Avinery, Elena, Firer, Michael A., Sherman, Michael Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688317/ https://www.ncbi.nlm.nih.gov/pubmed/36429097 http://dx.doi.org/10.3390/cells11223671 |
Ejemplares similares
-
Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Chronic Lymphocytic Leukemia In Vivo
por: Guzev, Ekaterina, et al.
Publicado: (2022) -
Hsp70–Bag3 Module Regulates Macrophage Motility and Tumor Infiltration via Transcription Factor LITAF and CSF1
por: Avinery, Lena, et al.
Publicado: (2022) -
A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects
por: Hesin, Arkadi, et al.
Publicado: (2022) -
Cytoplasmic proteotoxicity regulates HRI-dependent phosphorylation of eIF2α via the Hsp70-Bag3 module
por: Patel, Shivani, et al.
Publicado: (2022) -
Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks
por: Kumar, Santosh, et al.
Publicado: (2023)